公开(公告)号：US20230365537A1

公开(公告)日：2023-11-16

申请号：US18308441

申请日：2023-04-27

申请人： ORIC Pharmaceuticals, Inc.

发明人： Chudi NDUBAKU ,  Jared Thomas MOORE ,  Paul Anthony GIBBONS ,  Jae Hyuk CHANG ,  F. Anthony ROMERO ,  Xiaohui DU ,  Hiroyuki KAWAI ,  Stephane CIBLAT ,  Hong WANG ,  Vincent ALBERT ,  Lea CONSTANTINEAU-FORGET ,  Hugo de Almeida SILVA ,  Dilan Emine POLAT ,  Amit NAYYAR ,  Daniel Gordon Michael SHORE ,  Kejia WU ,  Joanne TAN

IPC分类号： C07D403/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/04

CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

摘要： Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240124426A1

公开(公告)日：2024-04-18

申请号：US18452278

申请日：2023-08-18

申请人： ORIC Pharmaceuticals, Inc.

发明人： Chudi NDUBAKU ,  Jared Thomas MOORE ,  Paul Anthony GIBBONS ,  Jae Hyuk CHANG ,  F. Anthony ROMERO ,  Xiaohui DU ,  Hiroyuki KAWAI ,  Stephane CIBLAT ,  Hong WANG ,  Vincent ALBERT ,  Lea CONSTANTINEAU-FORGET ,  Hugo de Almeida SILVA ,  Dilan Emine POLAT ,  Amit NAYYAR ,  Daniel Gordon Michael SHORE ,  Kejia WU ,  Joanne TAN

IPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

摘要： Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240270722A1

公开(公告)日：2024-08-15

申请号：US18558806

申请日：2022-05-10

申请人： ORIC Pharmaceuticals, Inc.

发明人： Chudi NDUBAKU ,  Jared Thomas MOORE ,  Paul Anthony GIBBONS ,  Jae Hyuk CHANG ,  F. Anthony ROMERO ,  Xiaohui DU ,  Hiroyuki KAWAI ,  Stephane CIBLAT ,  Hong WANG ,  Vincent ALBERT ,  Lea CONSTANTINEAU-FORGET ,  Hugo de Almeida SILVA ,  Dilan Emine POLAT ,  Amit NAYYAR ,  Daniel Gordon Michael SHORE ,  Kejia WU ,  Joanne TAN

IPC分类号： C07D403/12 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/675 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07F9/6558

CPC分类号： C07D403/12 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/675 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/048 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07F9/65583

摘要： Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I)